Significance and utility of plasma brain natriuretic peptide concentrations in patients with idiopathic ventricular arrhythmias

BACKGROUND: Secretion of B-type natriuretic peptide (BNP) appears to be regulated mainly by wall tension, and an increase in the plasma BNP concentration is considered to reflect ventricular structural and functional abnormalities. The aim of this study was to clarify the significance and utility of the measurement of the plasma BNP in the setting of idiopathic ventricular arrhythmias (I-VT/PVCs). METHODS: This study included 135 patients with symptomatic, monomorphic I-VT/PVCs (73 women; 53 +/- 17 years; 50 ventricular tachycardias [VTs], 85 premature ventricular contractions) who underwent radiofrequency catheter ablation. None had structural heart disease or renal dysfunction. RESULTS: The plasma BNP concentration exceeded the normal range (>18.4 pg/mL; high BNP concentration) in 79 patients (56%). The high BNP concentration was found more often in I-VT/PVCs originating from the left ventricle (LV; 74%) than the right ventricle (RV; 49%; P < 0.01). The plasma BNP concentration correlated with the age (P = 0.0001) and frequency of premature ventricular contractions (P < 0.0001), and left-sided I-VT/PVCs and the presence of controlled hypertension were independent predictors of a high BNP concentration (both P < 0.05). In patients with a successful ablation and high BNP concentration before the ablation, the BNP concentration decreased to the normal range in 61% of patients after ablation. In patients with a failed ablation, the BNP concentration did not decrease to the normal range after ablation in any of the patients (P < 0.0005). CONCLUSIONS: The plasma BNP concentration was elevated in about 60% of the patients with symptomatic I-VT/PVCs. Normalization of the high BNP concentration after ablation may indicate a successful ablation.     

右室不同部位起搏对左室重构及脑钠肽的影响

目的 比较右室流出道间隔部(RVS)与右室心尖部(RVA)起搏对左室重构及脑钠肽的影响.方法 60例具备起搏器植入指征的患者,随机分为RVA组与RVS组,分别于治疗前及治疗后6、12、24个月采血应用夹心酶联免疫吸附法检测血浆脑钠肽(BNP)水平,超声测量左心室舒张末期内径(LVEDD)、左室舒张末期容积(INEDV)和左室射血分数(LVEF),观察2组患者起搏前后心室重构指标及BNP的变化.结果 RVA组起搏术后各个时间点BNP水平显著升高[术后6、12、24个月分别为(108.2±29.8)、(190.3±46.7)、(308.2±56.5)ng/L],与术前[(60.2±15.7)ng/L]比较差异均有统计学意义(P均<0.05);RVS组起搏术后仅24个月时BNP水平较术前升高[(75.2±15.8)ng/L与(63.9±15.1)ng/L],差异有统计学意义(P<0.05).RVA起搏组随着起搏时间的延长,与术前相比,12个月时LVEDD、LVEDV增加,LVEF下降,差异均有统计学意义(P均<0.05).而RVS组LVEDD无明显增大,LVEDV轻度增加,LVEF呈下降趋势,差异均无统计学意义(P均>0.05).结论 RVS起搏较RVA起搏能改善心肌重构,改善左室功能.减轻神经内分泌激活.     

Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease

OBJECTIVE: To review information related to the accuracy of vancomycin serum drug concentrations in patients with end-stage renal disease, focusing on available assays and mechanisms of cross-reactivity. DATA SOURCES: Primary and review articles identified from a MEDLINE search (January 1980-June 1999) and through secondary sources. STUDY SELECTION AND DATA EXTRACTION: All articles identified were evaluated, and all relevant information was included in this review. DATA SYNTHESIS: Falsely elevated vancomycin serum concentrations may occur in patients with renal dysfunction. The underlying mechanism is due to the formation and accumulation of a pseudo-metabolite, the vancomycin crystalline degradation product (CDP). Vancomycin is converted to CDP when exposed to heat, including normal body temperature. Because the molecular structures of CDP and vancomycin are similar, both molecules are detected by polyclonal immunoassay systems used in clinical laboratories. This cross-reactivity leads to falsely elevated serum vancomycin concentrations in excess of 50-70%. Such large assay inaccuracies may result in improper dosage adjustments and therapeutic failures. A monoclonal immunoassay system has been developed that does not significantly cross-react with CDP. CONCLUSIONS: To appropriately interpret laboratory results, it is essential for clinicians to be aware of the vancomycin-CDP cross-reactivity problem and to be familiar with the specific assay used to measure vancomycin concentrations in patients with renal dysfunction.     

Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury

: This study was performed to elucidate the pathophysiological role of brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) in acute lung injury. : We sequentially measured plasma concentrations of immunoreactive BNP and ANP in 10 patients (mean age, 63 years) with acute lung injury and compared those with hemodynamic parameters and pulmonary functions. : Plasma concentrations of immunoreactive BNP and ANP were markedly elevated at entry into the study. Plasma BNP concentrations during the early course (3 days) showed significant (P < .01) positive correlations with systemic vascular resistance index (r = .708) and pulmonary vascular resistance index (r = .573), but a negative correlation with cardiac index (r = −.608). Plasma ANP concentrations showed a significant (P < .05) positive correlation with pulmonary capillary wedge pressure (r = .398). Plasma BNP in 4 patients who died and 1 patient with acute renal failure remained elevated during the entire hospital length of stay (12 days). : These findings suggest that circulating BNP plays an important role in acute lung injury along with ANP as a compensatory mechanism for cardiac dysfunction accompanied by increased systemic vascular resistance index and pulmonary vascular resistance index. Circulating BNP may be a sensitive humoral marker for the degree of ventricular dysfunction associated with acute lung injury.     

N-terminal pro-Brain natriuretic peptide as a useful biomarker for monitoring prognosis in patients with cardiac valve replacement

Background: N‐terminal pro‐Brain natriuretic peptide (NT‐proBNP) is an important biomarker to indicate cardiac function, but its significance in cardiac surgery is still unclear. Objective: To explore clinical significance of serum NT‐proBNP and their dynamic characteristics in patients with cardiac valve replacement (CVR). Methods: Dynamically detecting pre‐operative and postoperative serum NT‐proBNP on Elecsys 2010 in 60 CVR patients. Results: (1) There was a good relationship between pre‐operative NT‐proBNP and pre‐operative NYHA classification, ejection fraction, fractional shortening, or between postoperative 1 day log [NT‐proBNP] and postoperative ICU time, correlation coefficients were respectively 0.426 (P=0.001), ?0.465 (P=0.001), ?0.463 (P=0.002), and 0.453 (P=0.006). (2) Pre‐operative NT‐proBNP would be higher in multivalves damage or mitral lesions patients than that in single valve damage or aortic lesions. It indicated NT‐proBNP>1,352 pg/ml could discriminate multivalves damage in Rheumatic Heart Diseases (RHD) patients (sensitivity: 0.742; specificity: 0.64); and NT‐proBNP>549.12 pg/ml could differentiate mitral lesions and aortic lesions (sensitivity: 0.92; specificity: 0.75). However, pre‐operative serum NT‐proBNP for differentiating atrial fibrillation and sinus arrhythmia was not most efficient (AUC=0.655; P=0.044). (3) Perioperative NT‐proBNP in CVR patients was characterized by early postoperative NT‐proBNP increasing and late postoperative NT‐proBNP decreasing. The peak of postoperation NT‐proBNP was at postoperative 7 days. Conclusions: Serum NT‐proBNP was not only a good biomarker to effectively evaluate heart function but also to evaluate the cardiac valve damage in RHD patients, and postoperative NT‐proBNP dynamic determination, especially detecting postoperative 1 day, 7 days and 14 days NT‐proBNP would be more useful to evaluate prognosis of CVR patients. J. Clin. Lab. Anal. 25:149–155, 2011. © 2011 Wiley‐Liss, Inc.     

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

Using a specific radioimmunoassay for human brain natriuretic peptide (hBNP) with a monoclonal antibody, we have investigated its synthesis, secretion, and clearance in comparison with those of atrial natriuretic peptide (ANP) in normal subjects and patients with congestive heart failure (CHF). Mean BNP-like immunoreactivity (-LI) levels in normal atrium and ventricle were 250 and 18 pmol/g, respectively. The plasma BNP-LI level in normal subjects was 0.90 +/- 0.07 fmol/ml, which was 16% of the ANP-LI level. In contrast, the plasma BNP-LI level markedly increased in patients with CHF in proportion to its severity, and surpassed the ANP-LI level in severe cases. There was a significant step-up of the plasma BNP-LI level in the coronary sinus (CS) compared with that in the aortic root (Ao) and the difference between these BNP-LI levels, delta(CS-Ao)BNP, also increased with the severity of CHF. In addition, the step-up of the BNP-LI level in the anterior interventricular vein [delta(AIV-Ao)BNP] was comparable to delta(CS-Ao)BNP, indicating that BNP is secreted mainly from the ventricle. Predominant BNP synthesis in the ventricle was also confirmed by Northern blot analysis. Catheterization and pharmacokinetic studies revealed that hBNP is cleared from the circulation more slowly than alpha-hANP; this was in part attributed to lower (about 7%) binding affinity of hBNP to clearance receptors than that of alpha-hANP. A predominant molecular form of BNP-LI in the heart and plasma was a 3-kD form corresponding to hBNP. These results indicate that BNP is a novel cardiac hormone secreted predominantly from the ventricle, and that the synthesis, secretion and clearance of BNP differ from those of ANP, suggesting discrete physiological and pathophysiological roles of BNP in a dual natriuretic peptide system.     

Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure.

1. We have developed a radioimmunoassay for the measurement of immunoreactive brain natriuretic peptide (1-32) in human plasma. Simultaneous measurements of atrial natriuretic peptide have also been carried out to allow for direct comparison between circulating brain natriuretic peptide and atrial natriuretic peptide. Plasma levels of immunoreactive brain natriuretic peptide (means +/- SEM) were 1.1 +/- 0.1 pmol/l in 36 normal healthy subjects and were significantly elevated in cardiac transplant recipients (18.8 +/- 3.9 pmol/l, n = 12) and in patients with dialysis-independent (8.8 +/- 1.5 pmol/l, n = 11) or dialysis-dependent (41.6 +/- 8.8 pmol/l, n = 14) chronic renal failure. Similarly, in these groups of patients plasma levels of atrial natriuretic peptide were also significantly raised when compared with those in the group of normal healthy subjects. 2. The plasma level of atrial natriuretic peptide was significantly higher than that of brain natriuretic peptide in normal subjects and in patients with dialysis-independent chronic renal failure, with ratios (atrial natriuretic peptide/brain natriuretic peptide) of 2.8 +/- 0.2 and 2.2 +/- 0.3, respectively. However, in both cardiac transplant recipients and patients on dialysis plasma levels of atrial natriuretic peptide and brain natriuretic peptide were similar, with ratios of 1.3 +/- 0.2 and 1.0 +/- 0.1, respectively, in these two groups. 3. Plasma levels of brain natriuretic peptide and atrial natriuretic peptide were significantly correlated in the healthy subjects and within each group of patients. When all groups were taken together, there was an overall correlation of 0.90 (P < 0.001, n = 73).(ABSTRACT TRUNCATED AT 250 WORDS)     

Plasma brain natriuretic peptide as a biochemical marker for atrioventricular sequence in patients with pacemakers

We hypothesized that plasma brain natriuretic peptide, like plasma atrial natriuretic peptide, may reflect hemodynamic changes elicited by different cardiac pacing modes. The aim of this study was to investigate whether plasma brain natriuretic peptide could be influenced by different pacing modes or electrical stimulation. The subjects consisted of 164 patients with permanent pacemakers (52 VVI, 30 AAI, 82 DDD pacemakers) and unimpaired heart function. Patients with atrial fibrillation or spontaneous beats were excluded. Plasma atrial natriuretic peptide and brain natriuretic peptide levels were measured at a rate of 70 beats/min after 45 minutes in the supine position. Under ECG monitoring, the pacing mode was switched from DDD to VVI in 12 patients and from DDD to AAI in 4 patients with a dual chamber pacemaker. Plasma atrial natriuretic peptide and brain natriuretic peptide levels were also measured 30 minutes, 60 minutes, and 1 week after mode switching. Plasma atrial natriuretic peptide and brain natriuretic peptide levels were significantly higher in the nonphysiological pacing group than in the physiological pacing group, whereas these values were similar in the DDD and AAI pacing groups. One week after switching from DDD to VVI, plasma atrial natriuretic peptide and brain natriuretic peptide levels were significantly increased, however no significant changes were observed after switching to AAI. Based on a multivariate regression analysis of noninvasive clinical parameters, only a low plasma brain natriuretic peptide was significantly correlated with physiological pacing. We conclude that: (1) plasma brain natriuretic peptide, like atrial natriuretic peptide, is influenced by the pacing mode, but is not influenced by electrical stimulation; and (2) low plasma brain natriuretic peptide is important in relation to physiological pacing.     

终末期肾病患者大脑自发神经活动异常的静息态MR成像

目的采用基于静息态功能MRI(rs-fMRI)的低频振幅算法(ALFF)探讨终末期肾病(ESRD)患者大脑自发神经活动异常改变。方法纳入40例ESRD患者(男23例,女17例)及年龄、性别和教育年限相匹配的40例正常对照(HC)(男23例,女17例),采用神经心理学量表评估被试的认知功能并采集rs-fMRI数据。图像预处理后比较组间ALFF值的差异;提取ESRD组差异脑区的平均ALFF值与临床资料及神经认知量表进行相关性分析。结果ESRD患者存在多维度认知功能损害(P<0.01)。与HC相比,ESRD患者双侧楔前叶、左中央后回及左颞极:颞上回ALFF值显著降低,双侧小脑8区ALFF值显著升高(P<0.05,FWE校正)。双侧楔前叶平均ALFF值与红细胞(r=0.477,P=0.002;r=0.508,P=0.009)、血红蛋白(r=0.516,P<0.001;r=0.469,P=0.002)及红细胞比容(r=0.557,P<0.001;r=0.471,P=0.002)水平呈正相关。控制本实验涉及的所有临床变量后,发现右小脑8区与TMTA(r=0.597,P=0.003)及TMTB(r=0.555,P=0.007)呈正相关;左中央后回与FDST呈正相关(r=0.552,P=0.008)。结论ESRD患者整体认知功能受损;ESRD患者存在双侧楔前叶、左中央后回及左颞极:颞上回等参与认知活动脑区的自发脑活动受损;贫血可能影响ESRD患者大脑自发神经活动。     

重组人脑钠肽对房间隔缺损封堵术后的心脏重塑和心功能的影响

目的 研究重组人脑钠肽(recombinant human brain natriuretic peptide,rhBNP)对房间隔缺损(atrial septal defect,ASD)合并肺动脉高压(PAH)封堵术后的心脏重塑和心功能的影响.方法 ASD合并中重度PAH患者封堵成功患者60例,将其随机分为rhBNP组(28例)和对照组(32例),rhBNP组在动脉导管封堵术后即刻静脉应用rhBNP48小时,比较两组术前、术后48小时及术后6个月左心室舒张末内径、左心室舒张末容积、右心室内径及射血分数的变化.结果 治疗前rhBNP组和对照组左心室舒张末容积和内径、左心室射血分数和右心室内径之间差异无统计学意义(P＞0.05),随着治疗时间的延长,两组的左心室舒张末内径和容积、左心室射血分数均有上升趋势,两组右心室内径有下降趋势,组间、不同时点以及组间·不同时点的差异均有统计学意义(P＜0.05),两组间的左心室舒张末内径和客积和左心室射血分数上升和右心室内径下降趋势有所不同,rhBNP组较对照组上升(下降)差异有统计学意义(P＜0.05),术后6个月差异更明显.结论 静脉滴注rhBNP可在ASD封堵术后进一步缓解心室重塑,改善心功能.     

Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure.

1. Plasma human brain natriuretic peptide-like immunoreactivity (hBNP-li) was measured in ten patients with chronic renal failure before and after 4 h of haemodialysis. 2. Plasma hBNP-li was elevated in all patients before dialysis (mean +/- SEM 21.0 +/- 3.8 pmol/l) compared with healthy control subjects (1.3 +/- 0.2 pmol/l, n = 11), but showed considerable inter-patient variability. Before dialysis plasma hBNP-li bore no relationship to the serum creatinine level or to the mean blood pressure. 3. Plasma hBNP-li fell significantly (P = 0.04) during 4 h of haemodialysis. The fall in plasma hBNP-li correlated significantly with the degree of postural blood pressure drop (r2 = 0.44, P = 0.05) and with the fall in body weight (r2 = 0.64, P less than 0.01) after haemodialysis. In all patients, plasma hBNP-li at the end of treatment remained above that in healthy subjects. 4. There was no significant correlation between the fall in plasma hBNP-li and the fall in serum creatinine level, and between the fall in plasma hBNP-li and the fall in supine systolic or diastolic blood pressure, during haemodialysis. 5. We have shown that plasma hBNP-li is elevated in patients with chronic renal failure and is decreased during haemodialysis. The fact that the plasma hBNP-li was not reduced to normal by haemodialysis despite restoration to normovolaemia gives tentative support to the view that, in addition to hypervolaemia, another factor may also be responsible for the elevated plasma hBNP-li seen in these patients.     

急性心肌梗死患者血清N末端B型钠尿肽检测在左室重构中的预测价值

目的观察AMI患者发病第3天血清NT-proBNP水平与其左室重构之间的关系,评价其对AMI后左室重构的预测价值。方法以急性心肌梗死(AMI)发病第3天与3个月时患者的左心室舒张末期内径之差(△LVDd)>5 mm以及发病3个月时左心室射血分数(LVEF)≤40％作为发生心脏左室重构的依据。采用免疫电化学发光法测定106例患前壁、前间壁及前侧壁AMI的患者第3天血清NT-proBNP水平,分别对患者第3天和3个月时行超声心动描述术检测LVDd和LVEF水平。结果AMI患者第3天血清NT-proBNP均值是1039．28(241．50～1184．25)ng／L。AMI患者第3天和3个月时LVDd由(50±5)mm升至(53±7)mm(P<0．05),LVEF由(53±8)％升高为(54±11)％(P>0．05)。AMI后第3天NT-proBNP浓度与△LVDd呈显著正相关r=0．403(P<0．05),与LVEF呈显著负相关r=-0．395(P<0．01);ROC曲线分析表明以AMI发病3个月间△LVDd>5 mm作为发生左室重构的依据,曲线下面积(AUC)为0．894;以AMI发病3个月时LVEF≤40％作为发生左室重构的依据,则AUC为0．873;以AMI发病3个月间ALVDd>5 mm和3个月时LVEF≤40％作为发生左室重构的依据,则AUC为0．893。结论AMI患者第3天血清NT-proBNP水平可作为预测AMI晚期的左室重构指标之一。     

Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease

OBJECTIVES: We wanted to study the imbalance between antioxidant and oxidant generating systems resulting in oxidative stress (SOX) in end-stage renal disease (ESRD). We suggest that the plasma levels of Cu/Zn superoxide dismutase (Cu/Zn SOD) may be a new, sensitive marker of SOX in this population. DESIGN AND METHODS: We measured the levels of Cu/Zn SOD and the traditional SOX markers-malondialdehyde (MDA), total peroxide, and autoantibodies against oxidized LDL (OxLDL-Ab) in the plasma of 132 uremic patients. In addition, circulating enzyme levels were analyzed in relation to the inflammation and presence of diabetes mellitus (DM). RESULTS: Cu/Zn SOD levels were significantly higher in chronic renal failure (CRF) patients (P < 0.05), and in both dialyzed groups (both P < 0.001) than in controls, and were positively correlated with MDA, creatinine (both P < 0.001) and OxLDL-Ab (P < 0.01) in the whole uremic group. CONCLUSIONS: The plasma levels of Cu/Zn SOD may be a simple, sensitive marker of SOX in ESRD, independent from DM and inflammation.     

透析治疗对终末期肾病患者左心室肥厚的影响

目的 探讨不同透析方式-血液透析(HD)和腹膜透析(PD)对终末期肾病患者左心室肥厚(LVH)的影响及相关因素.方法入选透析中心透析龄大于3月的HD患者48例和PD惠者62例,并选取慢性肾脏病(CKD)3～5期患者43例作为对照.所有患者均测量血压、血容量、生化指标,行超声心动图检查,获得左心室质量指数(LVMI);HD患者于透后1小时内检查.PD和CKD患者于每月门诊复诊时空腹状态下检查.结果 3组患者的基线资料差异无统计学意义.HD患者的收缩(SBP)(156.7±28.4)mmHg明显高于PD(147.7±20.6)mmHg(P<0.05)和CKD患者(143.4±21.9)mmHg(P<0.01);HD患者透后的细胞外液(ECW)(14.51±2.51)L低于PD(15.67±3.26)L和CKD患者(15.84±3.27)L(P均<0.05);HD患者的LVMI 137.6±38.5显著高于PD 116.2±34.5和CKD患者104.5±30.0(均P<0.01),而PD和CKD患者的LVMI比较差异无统计学意义.根据Framingham标准HD、PD、CKD患者LVH发生率分别为68.8%、45.2%、32.6%.多元逐步回归分析显示SBP、透析方式(HD)、ECW均为LVMI的独立预测因素(r2=0.364,P<0.01).结论HD较PD患者展现出更高更严重的LVH.LVH与高血压、容量超负荷等有关.     

Serum brain natriuretic peptide in children with Kawasaki disease

BACKGROUND:

Kawasaki disease (KD) is a common cause of acquired heart disease in children. Recent studies have focused on the biochemical markers of the myocardium, their high sensitivity and specificity and significance in the diagnosis of KD. This study aimed to determine the serum level of brain natriuretic peptide (BNP) and its relation with the heart function of children with KD and to explore its clinical value in diagnosis of KD.

METHODS:

Forty-three KD children, aged from 5 months to 8 years (mean 2.3±0.6 years), were admitted to Qingdao Children’s Hospital from February 2007 to April 2009. Among them 27 were male, and 16 female. The 43 patients served as a KD group. Patients with myocarditis, cardiomyopathy, congenital heart disease and other primary heart diseases were excluded. Thirty healthy children, aged from 3 months to 15 years (mean 2.5±0.8 years) or 17 males and 13 females served as a control group. There were no significant differences in age and gender between the two groups (P>0.05). In the KD group, ELISA was used to measure the levels of serum BNP in acute and convalescent stages; and in the control group, the levels of serum BNP were measured once randomly. Left ventricular ejection fraction (LVEF), left ventricular shorten fraction (LVSF), cardiac index (CI) and left ventricular inflow velocity through the mitral annulus (including E-velocity and A-velocity) were measured by two-dimensional echocardiography in the acute and convalescent stages in the KD group. All data were expressed as mean±SD. The methods of analysis included Student’s t test and the linear regression analysis test. P<0.05 was considered statistically significant.

RESULTS:

The level of serum BNP in the acute stage (517.26±213.40) ng/ml was significantly higher than that in the convalescent stage (91.56±47.97) ng/ml in the control group (37.55±7.56) ng/ml (P<0.01). The levels of LVEF, LVSF and CI in the acute stage were significantly lower than those in the convalescent stage (P<0.05), but the E/A level was not significantly different between the acute and convalescent stages (P>0.05). Linear regression analysis showed that the BNP level was negatively correlated with the levels of LVEF, LVSF and CI(r=-0.63, -0.52, -0.53, P<0.05), but not significantly correlated with the E/A level (r=-0.18, P>0.05).

CONCLUSION:

The levels of serum BNP are significantly increased in KD patients, and are negatively correlated with the levels of LVEF, LVSF, and CI. The detection of serum BNP level is of clinical significance in the diagnosis of KD.KEY WORDS: Natriuretic peptide, brain; Kawasaki disease; Ejection fraction; left ventricular; Shorten fraction, left ventricular; Cardiac index; E/A; Correlation; Children     

终末期肾病患者脑网络动态功能连接

目的 观察终末期肾病(ESRD)患者脑网络动态功能连接改变。方法 回顾性分析30例ESRD患者(ESRD组)与33名健康受试者(对照组),采用图论分析方法基于颅脑静息态功能MRI(rs-fMRI)对动态功能连接(dFC)参数进行组间比较,评估ESRD患者dFC与网络拓扑结构异常,并以Pearson相关性分析观察其与临床变量的相关性。结果 相比对照组,ESRD组时间分数与平均驻留时间在状态二下升高、状态三下减低(P均＜0.05),其异常功能连接主要见于默认模式网络、感觉运动网络、皮质下核、执行和注意网络、视觉网络、小脑网络内及网络间。ESRD组网络密度及双侧颞上回节点度均低于对照组(P均＜0.05)。ESRD组状态二、三下的功能连接及图论属性异常参数与其临床指标均无明显相关(P均＞0.05)。结论 ESRD患者存在与认知功能损伤有关的脑动态网络时间属性及网络拓扑结构异常。